Arbutus Biopharma Corporation Stock News

Nuveen Asset Management LLC bought a new stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) in the 2nd quarter, Holdings Channel reports. The fund bought 226,012 shares of the biopharmaceutical companys stock, valued at approximately $685,000. Several other institutional investors have also made changes to their positions in ABUS. Northern Trust Corp grew its stake []

Northern Trust Corp raised its position in Arbutus Biopharma Co. (NASDAQ:ABUS) by 441.9% in the second quarter, HoldingsChannel reports. The fund owned 719,159 shares of the biopharmaceutical companys stock after purchasing an additional 586,456 shares during the quarter. Northern Trust Corps holdings in Arbutus Biopharma were worth $2,179,000 as of its most recent SEC filing. []

During the last session, Arbutus Biopharma Corporation (NASDAQ:ABUS)s traded shares were 0.72 million, with the beta value of the company hitting 2.58. At the end of the trading day, the stocks price was $3.19, reflecting an intraday gain of 2.24% or $0.07. The 52-week high for the ABUS share is $5.87, that puts it down Arbutus Biopharma Corporation (NASDAQ: ABUS) Stock Dropped -21.62% Over A Month Are There Any Chances Of Growth? Read More »

Brokerages expect Arbutus Biopharma Co. (NASDAQ:ABUS) to post ($0.18) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma reported earnings per share of []

Equities analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to post sales of $3.39 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Arbutus Biopharmas earnings. The highest sales estimate is $3.47 million and the lowest is $3.30 million. Arbutus Biopharma reported sales of $2.39 million during the same []

Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnership/buyout of Arbutus Biopharma. AB-729 has proven to work in treating patients with Hepatitis B with si

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call Transcript

Are these penny stocks ready to short squeeze? The post 5 Short Squeeze Penny Stocks To Watch For November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commerciali

Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informat

WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commerci

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercial